NCT05695859View on ClinicalTrials.gov

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Breast Cancer Female
Interventions
DRUG

99mTc-DARPinG3 SPECT/CT

One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection

Trial Locations (1)

Unknown

Russia Tomsk NRMC, Tomsk

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER